For consistency with our in vitro data using carboplatin-resistant SKOV3 and OVCAR3 cell lines, which harbored truncating (effectively as null) and missense mutations, respectively, only ovarian cancer samples with truncating or missense mutations in the TP53 gene that were previously exposed to platinum drugs were assessed (Fig. 7C, D). This evidence concerns the gene TP53 and ovarian carcinoma.